<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Dated December 10, 1999
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Translation of registrant's name into English)
2350 Cohen Street
-----------------
Saint Laurent, Quebec Canada H4R 2N6
------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ______ Form 40-F X (commenced in calendar
----- year 1998)
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ____ No X
---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Registrant)
Date: December 10, 1999 By: /s/ David Moszkowski
-------------------------------------
David Moszkowski
Senior Vice President and
Chief Financial Officer
<PAGE>
Exhibit 99.1
------------
PRESS RELEASE
PHOENIX INTERNATIONAL DIVESTS PHARMACOLOGY UNIT
IN LAVAL, FRANCE
Montreal, Quebec - December 6, 1999 - Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research
Organizations (CROs), today announced the divestment of its pharmacology unit in
Laval, France, formerly ITEM Labo. The business has been sold for cash to
existing management at the site. The Company also announced plans to consolidate
its European Discovery and Pre-Clinical services in Lyon, France.
"Our clients using the Laval services will continue to be capably serviced,"
stated Lucien Steru, responsible for Phoenix International Europe and Asia. "The
decision to divest the pharmacology unit reflects our intent to streamline
operations."
"We are committed to focusing on our strategic assets," said Ian Lennox, Chief
Executive Officer of Phoenix International. "Consolidating operations at our
Lyon site is the best way to serve our more than 200 pre-clinical clients more
effectively."
To support the company's strategy to accelerate the drug development process
through its full service operations, Phoenix will now offer safety pharmacology
services at its Lyon facilities.
"Our ability to meet the growing need for complete safety assessment of new drug
candidates is a key to strengthening what is already a state-of-the-art facility
in Lyon," said Nigel Brown, head of Phoenix's Discovery and Preclinical
Services.
<PAGE>
About Phoenix International
Phoenix International Life Sciences Inc. is one of the world's leading contract
research organizations. The Company provides a wide spectrum of clinical,
analytical, preclinical, drug discovery support and ancillary services to the
pharmaceutical and biotechnology industries. Since beginning its operations in
1989, Phoenix International has grown to approximately 2,400 employees
worldwide, of whom more than 215 have either medical degrees or PhD's and over
240 others have masters level education. Headquartered in Montreal, Quebec, the
Company has operations throughout Europe and North America and research
facilities in Australia, Israel and South Africa. Phoenix International is on
the World Wide Web at www.pils.com.
------------
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
FOR MORE INFORMATION, PLEASE CONTACT:
ANALYST CONTACT:
DAVID MOSZKOWSKI, C.A.
Senior Vice President and Chief Financial Officer
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
--------------
MEDIA CONTACT:
RICHARD GAREAU
Director of Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
----------------
